Table 3.
Hepatitis B Virus Drug-Resistance Patterns by Sanger and Deep Sequencing at 6 and 12 Months of Lamivudine Exposure
| IDa | Month | HBV DNA log10 IU/mL | Resistance-associated Mutations |
|
|---|---|---|---|---|
| Sanger Sequence | Deep Sequences (Frequency)b | |||
| 84* | 6 | 3.9 | M204I/M | M204I (20) M204V (1) |
| 12 | 7.8 | M204V L180M | … | |
| 97 | 6 | 3.6 | None | M204I (7) |
| 12 | 6.5 | M204V L80I L180M | … | |
| 117 | 6 | 3.6 | None | M204I (32) M204V (2) |
| 12 | 6.1 | M204V L180M | … | |
| 136* | 6 | 2.3 | M204I/M | M204I (11) |
| 200 | 6 | 2.5 | None | M204I (3) |
| 12 | 8.3 | M204V L180M | … | |
| 212 | 6 | 3.9 | None | M204I (20) M204V (6) |
| 12 | 8.7 | M204V L180M A181S | … | |
| 221 | 6 | 2.3 | None | M204I (27) |
| 12 | 5.4 | M204V L180M | … | |
| 243 | 6 | 3.2 | None | M204I (9) M204V (1) A181T (1) |
| 12 | 8.8 | M204V L180M A181S | … | |
| 448 | 6 | 4.5 | None | M204I (3) |
| 12 | 8.0 | M204V L180M | … | |
| 457 | 6 | 4.9 | None | M204I (7) M204V (2) A181T (3) |
| 12 | 7.4 | M204V L180M | … | |
| 509 | 6 | 5.1 | None | M204I (8) M204V (2) A181T (1) |
| 12 | 4.4 | M204V L180M | … | |
| 592* | 6 | 5.0 | M204I/M | M204I (6) M204V (3) A181T (2) |
| 595* | 6 | 2.6 | M204I/M | M204I (14) |
| 668 | 6 | 4.3 | M204I/M | M204I (16) |
| 729* | 6 | 2.5 | M204I/M | M204I (14) V173L (2) |
| 12 | 7.6 | M204V V173L L180M | … | |
| 854 | 6 | 4.3 | None | M204I (6) M204V (3) V173L (46) |
| 12 | 6.3 | M204V V173L L180M | … | |
| 996 | 6 | 8.2 | None | None |
| 12 | 4.8 | None | M204I (2) | |
Abbreviations: HBV, hepatitis B virus; ID, identification number; RAM, resistance-associated mutation.
a Each subject is indicated by an ID number.
b Subjects with HBV DNA levels ≥300 IU/mL and sufficient stored sample available underwent deep sequencing (≥1% sensitivity), including five subjects at baseline (indicated by *), 17 at 6 months and one at 12 months. None of the baseline samples showed RAMs. The frequency (%) of mutants in the deep sequencing reads is indicated in brackets. The frequency of M204I in Sanger positive vs Sanger negative samples was median 14% vs 7% (P = .05).